Tarsus Pharmaceuticals (TARS) Stock Price, Quote, News & History

Comments

Tarsus Pharmaceuticals Inc (TARS) Stock Price, Quote, News & History

TARSNASDAQ

Trade with Public

$72.56

0.140.19%

At close: Apr 10, 5:00 PM EST

$72.56

N/A

After Hours: 4:00 PM EST

OverviewNews Earnings Options Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$72.72

Close

$72.56

Volume / Avg.

383.89K / 564.84K

Day Range

$71.52 - $73.33

52 Wk Range

38.51 - 85.25

Market Cap

$3.09B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

59

Short Interest

12.2%

Days to Cover

10.14

Recent Tarsus Pharmaceuticals Inc News

Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal

Elanco sells U.S. Xdemvy royalties to Blackstone for $295 million, aiming to lower debt and cut interest costs while retaining global rights.

Vandana Singh

Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday

Avi Kapoor

Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-12.45M

Investing Cash Flow (TTM)

-42.12M

Financing Cash Flow (TTM)

143.39M

Free Cash Flow (TTM)

-22.31M

Capital Expenditure (TTM)

-9.86M

Net Change in Cash (TTM)

88.82M

Analyst Trends and Forecast

1

Oct 25

2

Nov 25

1

Dec 25

2

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.74B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

6.70

PB Ratio (TTM)

8.97

Earnings Yield % (TTM)

-2.20%

Earnings Yield % (FWD)

-0.89%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$8.07

Company Debt

Total Debt

$72.44M

LT Debt

$72.44M

LT Debt Issuance (TTM)

$0

LT Debt Repayment (TTM)

-

Total Cash

$183.64M

Debt to Equity

0.21

Issuance of Debt (TTM)

$0

Repayment of Debt (TTM)

-

Key Statistics

Open

$72.72

Close

$72.56

Volume / Avg.

383.89K / 564.84K

Day Range

$71.52 - $73.33

52 Wk Range

38.51 - 85.25

Market Cap

$3.09B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

59

Short Interest

12.2%

Days to Cover

10.14

About

Sector

Health Care

Industry

Pharmaceuticals

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class the...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Tarsus Pharmaceuticals (TARS) stock?

A

You can purchase shares of Tarsus Pharmaceuticals (NASDAQ:TARS) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Tarsus Pharmaceuticals (TARS) competitors?

A

Other companies in Tarsus Pharmaceuticals’s space includes: Supernus Pharmaceuticals Inc (NASDAQ:SUPN), Phibro Animal Health Corp (NASDAQ:PAHC), Terns Pharmaceuticals Inc (NASDAQ:TERN), ANI Pharmaceuticals Inc (NASDAQ:ANIP) and Axsome Therapeutics Inc (NASDAQ:AXSM).

Q

What is the forecast, or price target, for Tarsus Pharmaceuticals (TARS) stock?

A

Tarsus Pharmaceuticals has a consensus price target of $76.90.

Q

What is the current price for Tarsus Pharmaceuticals (TARS)?

A

The stock price for Tarsus Pharmaceuticals (NASDAQ: TARS) is $72.56 last updated April 10, 2026 at 4:00 PM EDT.

Q

Does Tarsus Pharmaceuticals (TARS) pay a dividend?

A

There are no upcoming dividends for Tarsus Pharmaceuticals.

Q

When is Tarsus Pharmaceuticals (NASDAQ:TARS) reporting earnings?

A

Tarsus Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Tarsus Pharmaceuticals (TARS) going to split?

A

There is no upcoming split for Tarsus Pharmaceuticals.

Q

What sector and industry does Tarsus Pharmaceuticals (TARS) operate in?

A

Tarsus Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

People Also Watch

Supernus Pharmaceuticals Inc

NASDAQ:SUPN

$50.68

%

Phibro Animal Health Corp

NASDAQ:PAHC

$57.89

%

Terns Pharmaceuticals Inc

NASDAQ:TERN

$52.72

0.17%

ANI Pharmaceuticals Inc

NASDAQ:ANIP

$78.36

%

Axsome Therapeutics Inc

NASDAQ:AXSM

$178.11

%

Ocular Therapeutix Inc

Ligand Pharmaceuticals Inc

NASDAQ:LGND

$204.92

%

Key Statistics

Open

$72.72

Close

$72.56

Volume / Avg.

383.89K / 564.84K

Day Range

$71.52 - $73.33

52 Wk Range

38.51 - 85.25

Market Cap

$3.09B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

59

Short Interest

12.2%

Days to Cover

10.14

Recent Tarsus Pharmaceuticals Inc News

Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal

Elanco sells U.S. Xdemvy royalties to Blackstone for $295 million, aiming to lower debt and cut interest costs while retaining global rights.

Vandana Singh

Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday

Avi Kapoor

Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-12.45M

Investing Cash Flow (TTM)

-42.12M

Financing Cash Flow (TTM)

143.39M

Free Cash Flow (TTM)

-22.31M

Capital Expenditure (TTM)

-9.86M

Net Change in Cash (TTM)

88.82M

Analyst Trends and Forecast

1

Oct 25

2

Nov 25

1

Dec 25

2

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.74B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

6.70

PB Ratio (TTM)

8.97

Earnings Yield % (TTM)

-2.20%

Earnings Yield % (FWD)

-0.89%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$8.07

Company Debt

Total Debt

$72.44M

LT Debt

$72.44M

LT Debt Issuance (TTM)

$0

LT Debt Repayment (TTM)

-

Total Cash

$183.64M

Debt to Equity

0.21

Issuance of Debt (TTM)

$0

Repayment of Debt (TTM)

-

Key Statistics

Open

$72.72

Close

$72.56

Volume / Avg.

383.89K / 564.84K

Day Range

$71.52 - $73.33

52 Wk Range

38.51 - 85.25

Market Cap

$3.09B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

59

Short Interest

12.2%

Days to Cover

10.14

About

Sector

Health Care

Industry

Pharmaceuticals

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class the...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry